Macugen for Histoplasmosis

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

NCT00406107 ·Status: COMPLETED ·Phase: PHASE4

Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.

NCT00820742 ·Status: WITHDRAWN

An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD

NCT00327470 ·Status: TERMINATED ·Phase: PHASE4

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

NCT01573572 ·Status: COMPLETED ·Phase: PHASE4

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

NCT00088283 ·Status: COMPLETED ·Phase: PHASE2

Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)

NCT01486771 ·Status: UNKNOWN ·Phase: PHASE4

Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions

NCT00324116 ·Status: COMPLETED ·Phase: PHASE4

A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema

NCT01487044 ·Status: AVAILABLE

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

NCT00605280 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula

NCT00040313 ·Status: COMPLETED ·Phase: PHASE2

Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)

NCT00446381 ·Status: COMPLETED ·Phase: NA

Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)

NCT00088192 ·Status: COMPLETED ·Phase: NA

Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice

NCT00787319 ·Status: COMPLETED

A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy

NCT01487070 ·Status: COMPLETED ·Phase: PHASE1

Subretinal Macugen® for Neovascular Age-Related Macular Degeneration

NCT00788177 ·Status: UNKNOWN ·Phase: PHASE3

Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

NCT00134667 ·Status: TERMINATED ·Phase: PHASE4

A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD

NCT00354445 ·Status: UNKNOWN ·Phase: PHASE4

Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa

NCT02140164 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration

NCT01154062 ·Status: COMPLETED ·Phase: PHASE1

Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration

NCT00239928 ·Status: COMPLETED ·Phase: PHASE2

Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.

NCT01281098 ·Status: COMPLETED ·Phase: PHASE2

Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study

NCT01486238 ·Status: COMPLETED ·Phase: PHASE4

A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

NCT01678872 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)

NCT00150202 ·Status: COMPLETED ·Phase: PHASE3

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT06161584 ·Status: ACTIVE_NOT_RECRUITING